Evidence map›Paper›PMID 29960633›Full record

Trial reportThe journal of sexual medicine2018

Validity and Clinically Meaningful Changes in the Psychosexual Daily Questionnaire and Derogatis Interview for Sexual Function Assessment: Results From the Testosterone Trials.

Christina Wang, Alisa J Stephens-Shields, Leonard R DeRogatis, Glenn R Cunningham, Ronald S Swerdloff, Peter Preston, David Cella, Peter J Snyder, Thomas M Gill, Shalender Bhasin and 2 more

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in The journal of sexual medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Christina WangDivision of Endocrinology, Department of Medicine, Harbor-University of California, Los Angeles Medical Center and Los Angeles Biomedical Research Institute, Torrance, CA, USA. Electronic address: wang@labiomed.org.
Alisa J Stephens-ShieldsDepartment of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Leonard R DeRogatisDepartment of Psychiatry, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Glenn R CunninghamDivision of Diabetes, Endocrinology, and Metabolism, Baylor College of Medicine and Baylor St Luke's Medical Center, Houston, TX, USA.
Ronald S SwerdloffDivision of Endocrinology, Department of Medicine, Harbor-University of California, Los Angeles Medical Center and Los Angeles Biomedical Research Institute, Torrance, CA, USA.
Peter PrestonDepartment of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
David CellaDepartment of Medical Social Science, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Peter J SnyderDivision of Endocrinology, Diabetes, and Metabolism, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Thomas M GillSection of Geriatrics, Department of Medicine, Yale School of Medicine, New Haven, CT, USA.
Shalender BhasinResearch Program in Men's Health: Aging and Metabolism; Boston Claude D. Pepper Older Americans Independence Center; Harvard Medical School; Brigham and Women's Hospital, Boston, MA, USA.
Alvin M MatsumotoGeriatric Research, Education and Clinical Center, Department of Veterans Affairs Puget Sound Health Care System, and Division of Gerontology and Geriatric Medicine, Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA.
Raymond C RosenHealthCore/New England Research Institutes Inc, Watertown, MA, USA.

Funding

UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
Yale Study Support Suite (YES3): Dashboard and Web Portal Software Supporting Research Workflow through integrated, customizable REDCap External ModulesP30AG021342 · NIA · YALE UNIVERSITY · PI Albert C Shaw · 2002 to 2026
$37.9M
Testosterone TrialU01AG030644 · NIA · UNIVERSITY OF PENNSYLVANIA · PI SNYDER, PETER J. · 2009 to 2015
$32.4M
ACADEMIC LEADERSHIP AWARD IN DISABILITY AND DISABLING DISORDERSK07AG043587 · NIA · YALE UNIVERSITY · PI GILL, THOMAS MICHAEL · 2013 to 2017
$645k
NCATS NIH HHS UL1 TR001881NIA NIH HHS K07 AG043587NIA NIH HHS P30 AG021342NIA NIH HHS U01 AG030644
6 · The paper itself

Abstract

backgroundLimited information is available on the performance characteristics of 2 questionnaires commonly used in clinical research, the Psychosexual Daily Questionnaire (PDQ) and the Derogatis Interview for Sexual Function (DISF)-II Assessment, especially in older men with low testosterone (T) and impaired sexual function.

aimTo determine reliability of PDQ and DISF-II by assessing the correlation within and between domains in the questionnaires and to define clinically meaningful changes in sexual activity (PDQ question 4 [Q4]) and desire (DISF-II sexual desire domain [SDD]) domains.

methodsData from 470 men participating in the T Trials were used to calculate Spearman correlation coefficients of individual items and total score among questionnaires to determine convergent and construct validity. Clinically meaningful changes for sexual desire and activity were determined by randomly dividing the sample into training and validation sets. Anchor- and distribution-based clinically meaningful change criteria were defined in the training set, and selected changes were evaluated in the validation set. OUTCOMES: Validity of the PDQ and DISF-II and clinically meaningful changes in sexual desire and activity were determined in older men in T Trials.

resultsModerate to strong correlations were shown within and between domains from different questionnaires. Using Patient Global Impression of Change as an anchor, clinically meaningful change in PDQ sexual activity was ≥0.6, and in DISF-SDD was ≥5.0. Applying these change cut-points to the validation set, a greater proportion of T-treated men achieved clinically meaningful improvement in their sexual desire and activity compared to placebo-treated men. CLINICAL IMPLICATIONS: The PDQ-Q4 and DISF-II-SDD can be used to reliably assess clinically meaningful changes in sexual activity and sexual desire in hypogonadal men treated with T. STRENGTHS & LIMITATIONS: Strengths of this study include a large sample size, long trial duration, and inclusion of men with low libido and unequivocally low T levels. Limitations include using data from a single study that enrolled only older hypogonadal men, and only 1 anchor for both sexual desire and activity.

conclusionModerate to strong correlations were demonstrated within and between different sexual domains of the PDQ and DISF-II confirming construct and convergent validity. Clinically meaningful improvement in elderly hypogonadal men was change of ≥0.6 score in the PDQ-Q4 and ≥5.0 in the DISF-SDD. Improvements in sexual activity and desire in the T Trials were modest but clinically meaningful. Wang C, Stephens-Shields AJ, DeRogatis LR, et al. Validity and Clinically Meaningful Changes in the Psychosexual Daily Questionnaire and Derogatis Interview for Sexual Function Assessment: Results From the Testosterone Trials. J Sex Med 2018;15:997-1009.

Indexed as

AgedDouble-Blind MethodHumansLibidoMalePenile ErectionReproducibility of ResultsSexual BehaviorSexual Dysfunction, PhysiologicalSurveys and QuestionnairesTestosteroneTestosteroneClinically Meaningful ChangeErectile FunctionSexual ActivitySexual DesireSexual Function AssessmentTestosterone DeficiencyTestosterone Treatment in Older MenTestosterone Trials

Identifiers

PMID29960633
PMCPMC6435333

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.